コーパス検索結果(共起頻度の集計）
検索語: remain
ヒット件数: 1000
| 一般的な頻出語を「文章内」のリストから除外しています |
| 2語前 |
1語前 |
|
1語後 |
2語後 |
|
文章内 |
| of |
41 |
the |
50 |
|
unclear |
141 |
understood |
61 |
|
however |
233 |
| this |
39 |
it |
47 |
|
unknown |
71 |
unknown |
40 |
|
unclear |
144 |
| and |
31 |
has |
33 |
|
poorly |
69 |
be |
35 |
|
unknown |
115 |
| the |
28 |
and |
20 |
|
largely |
64 |
in |
27 |
|
mechanisms |
103 |
| however |
26 |
mechanisms |
16 |
|
a |
53 |
the |
27 |
|
cells |
81 |
| these |
25 |
have |
14 |
|
elusive |
44 |
whether |
20 |
|
although |
80 |
| in |
23 |
cells |
12 |
|
to |
35 |
to |
19 |
|
poorly |
72 |
| such |
10 |
there |
12 |
|
controversial |
23 |
how |
16 |
|
despite |
71 |
| but |
10 |
questions |
10 |
|
the |
19 |
and |
16 |
|
understood |
68 |
| molecular |
10 |
but |
10 |
|
challenging |
17 |
defined |
13 |
|
largely |
66 |
| for |
9 |
still |
9 |
|
incompletely |
17 |
challenge |
12 |
|
patients |
62 |
| underlying |
9 |
that |
9 |
|
in |
16 |
for |
12 |
|
associated |
52 |
| it |
8 |
process |
8 |
|
obscure |
14 |
unexplored |
10 |
|
cell |
51 |
| cancer |
8 |
mechanism |
7 |
|
significant |
14 |
with |
9 |
|
underlying |
51 |
| to |
8 |
function |
7 |
|
stable |
13 |
after |
9 |
|
yet |
50 |
| its |
7 |
development |
7 |
|
uncertain |
12 |
of |
9 |
|
mechanism |
49 |
| with |
6 |
however |
7 |
|
unchanged |
10 |
significant |
8 |
|
elusive |
48 |
| disease |
5 |
to |
7 |
|
an |
9 |
patients |
8 |
|
molecular |
48 |
| on |
5 |
responses |
6 |
|
limited |
8 |
characterized |
8 |
|
role |
45 |
| tumor |
4 |
also |
6 |
|
at |
7 |
major |
8 |
|
during |
43 |
| membrane |
4 |
mortality |
6 |
|
unresolved |
6 |
as |
7 |
|
disease |
41 |
| during |
4 |
action |
6 |
|
significantly |
6 |
constrained |
5 |
|
significant |
41 |
| that |
4 |
disease |
5 |
|
constant |
5 |
however |
5 |
|
treatment |
40 |
| is |
4 |
tissues |
5 |
|
about |
5 |
despite |
5 |
|
risk |
39 |
| gene |
4 |
activity |
5 |
|
one |
5 |
because |
5 |
|
specific |
37 |
| or |
3 |
interactions |
5 |
|
on |
5 |
during |
5 |
|
many |
36 |
| treatment |
3 |
this |
4 |
|
unexplored |
4 |
by |
5 |
|
high |
34 |
| mechanisms |
3 |
activation |
4 |
|
relatively |
4 |
leading |
4 |
|
activity |
34 |
| brain |
3 |
expression |
4 |
|
high |
4 |
than |
4 |
|
function |
34 |
| protective |
3 |
formation |
4 |
|
difficult |
4 |
under |
4 |
|
cancer |
33 |
| their |
3 |
biology |
4 |
|
ill |
4 |
at |
4 |
|
one |
32 |
| many |
3 |
interaction |
4 |
|
undefined |
3 |
even |
3 |
|
development |
31 |
| tissue |
3 |
changes |
4 |
|
associated |
3 |
especially |
3 |
|
functional |
31 |
| developmental |
3 |
processes |
4 |
|
scarce |
3 |
uncharacterized |
3 |
|
gene |
31 |
| significant |
3 |
gaps |
4 |
|
intact |
3 |
may |
3 |
|
only |
30 |
| yet |
3 |
patients |
4 |
|
approximately |
3 |
over |
3 |
|
human |
29 |
| cells |
3 |
cancer |
4 |
|
unidentified |
3 |
but |
3 |
|
95 |
28 |
| by |
3 |
or |
3 |
|
of |
3 |
due |
3 |
|
signaling |
27 |
| biological |
2 |
human |
3 |
|
almost |
3 |
are |
3 |
|
increased |
27 |
| glucose |
2 |
models |
3 |
|
patients |
3 |
elusive |
3 |
|
proteins |
27 |
| risk |
2 |
infection |
3 |
|
partially |
3 |
associated |
3 |
|
expression |
27 |
| circuit |
2 |
plasticity |
3 |
|
less |
3 |
mystery |
3 |
|
challenge |
26 |
| related |
2 |
structure |
3 |
|
regarding |
3 |
particularly |
3 |
|
long |
26 |
| pathways |
2 |
can |
3 |
|
uncharacterized |
3 |
same |
3 |
|
c |
26 |
| tumour |
2 |
methods |
3 |
|
as |
3 |
effective |
3 |
|
all |
26 |
| mammalian |
2 |
response |
3 |
|
poor |
3 |
unclear |
3 |
|
known |
26 |
| functional |
2 |
differentiation |
3 |
|
statistically |
3 |
questions |
2 |
|
both |
26 |
| antagonistic |
2 |
vivo |
3 |
|
highly |
3 |
most |
2 |
|
different |
26 |
| all |
2 |
effects |
3 |
|
uncontrolled |
3 |
need |
2 |
|
effects |
26 |
| vivo |
2 |
who |
3 |
|
elevated |
2 |
key |
2 |
|
levels |
25 |
| human |
2 |
stimuli |
3 |
|
sparse |
2 |
partially |
2 |
|
cellular |
25 |
| daily |
2 |
outcomes |
3 |
|
17 |
2 |
although |
2 |
|
p |
24 |
| bacterial |
2 |
proteins |
3 |
|
and |
2 |
suggesting |
2 |
|
time |
24 |
| microtubule |
2 |
inflammation |
3 |
|
low |
2 |
primary |
2 |
|
understanding |
24 |
| 0001 |
2 |
progression |
3 |
|
substantial |
2 |
low |
2 |
|
ci |
23 |
| k |
2 |
properties |
3 |
|
soluble |
2 |
1 |
2 |
|
responses |
23 |
| addition |
2 |
programs |
3 |
|
active |
2 |
identified |
2 |
|
controversial |
23 |
| clinical |
2 |
transformation |
3 |
|
only |
2 |
when |
2 |
|
use |
23 |
| viral |
2 |
hf |
2 |
|
underexplored |
2 |
increased |
2 |
|
major |
22 |
| diabetes |
2 |
connectivity |
2 |
|
5 |
2 |
unchanged |
2 |
|
important |
22 |
| whereas |
2 |
basis |
2 |
|
dynamically |
2 |
lesions |
2 |
|
two |
22 |
| than |
2 |
actions |
2 |
|
viable |
2 |
which |
2 |
|
identified |
22 |
| important |
2 |
loss |
2 |
|
enigmatic |
2 |
functional |
2 |
|
brain |
22 |
| recent |
2 |
suppression |
2 |
|
unsolved |
2 |
constant |
2 |
|
infection |
22 |
| parasite |
2 |
heterogeneity |
2 |
|
below |
2 |
clear |
2 |
|
protein |
22 |
| state |
2 |
dynamics |
2 |
|
true |
2 |
about |
2 |
|
regulation |
22 |
| nk |
2 |
glioblastoma |
2 |
|
higher |
2 |
until |
2 |
|
genes |
21 |
| has |
2 |
proteome |
2 |
|
undiagnosed |
2 |
stable |
2 |
|
studies |
21 |
| memory |
2 |
assembly |
2 |
|
transcriptionally |
2 |
a |
2 |
|
other |
21 |
| surgery |
2 |
pain |
2 |
|
debated |
2 |
or |
2 |
|
data |
20 |
| autoimmune |
2 |
membrane |
2 |
|
unaffected |
2 |
formidable |
2 |
|
response |
20 |
| tgf |
2 |
effect |
2 |
|
such |
2 |
obscure |
2 |
|
t |
20 |
| approaches |
2 |
subjects |
2 |
|
little |
2 |
cells |
2 |
|
years |
20 |
| other |
2 |
infections |
2 |
|
challenges |
2 |
7 |
2 |
|
low |
20 |
| shock |
2 |
network |
2 |
|
0 |
2 |
higher |
2 |
|
structure |
20 |
| 5 |
2 |
signaling |
2 |
|
cost |
2 |
debate |
2 |
|
changes |
19 |
| 1 |
2 |
gap |
2 |
|
tenuous |
2 |
sensitive |
2 |
|
processes |
19 |
| n |
2 |
growth |
2 |
|
six |
2 |
active |
2 |
|
dynamics |
19 |
| l1 |
2 |
materials |
2 |
|
untested |
2 |
our |
2 |
|
challenging |
19 |
| cellular |
2 |
motions |
2 |
|
incomplete |
2 |
silent |
2 |
|
virus |
19 |
| formation |
2 |
temperature |
2 |
|
very |
2 |
neglected |
2 |
|
into |
19 |
| time |
2 |
treatment |
2 |
|
three |
2 |
critical |
2 |
|
n |
19 |
| rates |
2 |
rate |
2 |
|
immobile |
1 |
among |
1 |
|
s |
18 |
| regulatory |
2 |
diseases |
2 |
|
important |
1 |
hampering |
1 |
|
formation |
18 |
| complex |
2 |
communities |
2 |
|
unstudied |
1 |
mainly |
1 |
|
about |
18 |
| hematological |
2 |
mutants |
2 |
|
elucidating |
1 |
main |
1 |
|
hiv |
18 |
| specific |
2 |
oil |
2 |
|
inconclusive |
1 |
hr |
1 |
|
conditions |
18 |
| induced |
2 |
of |
2 |
|
codons |
1 |
15 |
1 |
|
mortality |
17 |
| whose |
2 |
which |
2 |
|
open |
1 |
strong |
1 |
|
models |
17 |
| throughput |
2 |
complications |
2 |
|
seizure |
1 |
unscathed |
1 |
|
model |
17 |
| behavior |
1 |
brain |
2 |
|
exposed |
1 |
free |
1 |
|
factors |
17 |
| diseases |
1 |
cases |
2 |
|
full |
1 |
scientific |
1 |
|
pathways |
17 |
| types |
1 |
area |
2 |
|
6 |
1 |
multiparametric |
1 |
|
resistance |
17 |
| developing |
1 |
women |
2 |
|
unaltered |
1 |
propensity |
1 |
|
complex |
17 |
| graft |
1 |
relationships |
2 |
|
lower |
1 |
genomes |
1 |
|
stable |
17 |
| cycle |
1 |
interface |
2 |
|
effective |
1 |
80 |
1 |
|
control |
17 |
| open |
1 |
use |
2 |
|
closed |
1 |
indicating |
1 |
|
incompletely |
17 |
| dated |
1 |
conditions |
2 |
|
critical |
1 |
up |
1 |
|
biological |
16 |
| acheulean |
1 |
challenges |
2 |
|
hotspots |
1 |
prompting |
1 |
|
obscure |
16 |
| her2 |
1 |
behavior |
2 |
|
present |
1 |
variability |
1 |
|
factor |
16 |
| overall |
1 |
networks |
2 |
|
off |
1 |
ert |
1 |
|
type |
16 |
| signaling |
1 |
risk |
2 |
|
many |
1 |
consistent |
1 |
|
because |
16 |
| lattice |
1 |
enhancement |
2 |
|
obstacles |
1 |
neanderthals |
1 |
|
clinical |
16 |
| ventricular |
1 |
species |
2 |
|
unanswered |
1 |
subject |
1 |
|
results |
16 |
| br |
1 |
more |
2 |
|
completely |
1 |
steady |
1 |
|
induced |
16 |
| coke |
1 |
system |
2 |
|
26 |
1 |
unperturbed |
1 |
|
significance |
16 |
| mtor |
1 |
microresonators |
2 |
|
capable |
1 |
matter |
1 |
|
research |
16 |
| may |
1 |
beta |
2 |
|
static |
1 |
svhigh |
1 |
|
neural |
16 |
| laws |
1 |
vaccination |
2 |
|
lung |
1 |
gold |
1 |
|
physiological |
16 |
| defect |
1 |
tuberculosis |
2 |
|
34 |
1 |
9 |
1 |
|
impact |
16 |
| band |
1 |
cs |
2 |
|
connected |
1 |
modular |
1 |
|
process |
16 |
| artificial |
1 |
condition |
2 |
|
stationary |
1 |
there |
1 |
|
over |
16 |
| cell |
1 |
years |
2 |
|
untreated |
1 |
throughout |
1 |
|
defined |
16 |
| thereafter |
1 |
homeostasis |
2 |
|
teeth |
1 |
percentage |
1 |
|
no |
16 |
| mature |
1 |
much |
2 |
|
prevailing |
1 |
if |
1 |
|
dna |
16 |
| at |
1 |
rates |
2 |
|
mutations |
1 |
early |
1 |
|
species |
16 |
| chemotherapy |
1 |
regulated |
2 |
|
members |
1 |
thirds |
1 |
|
limited |
16 |
| hippocampal |
1 |
connections |
2 |
|
two |
1 |
cac5y |
1 |
|
rates |
16 |
| cultures |
1 |
associations |
2 |
|
independently |
1 |
since |
1 |
|
compared |
15 |
| megalin |
1 |
association |
2 |
|
diffusive |
1 |
who |
1 |
|
through |
15 |
| coinfected |
1 |
profiles |
2 |
|
impossible |
1 |
intense |
1 |
|
highly |
15 |
| constitutes |
1 |
malignancies |
2 |
|
crucial |
1 |
untouched |
1 |
|
used |
15 |
| while |
1 |
they |
2 |
|
related |
1 |
62 |
1 |
|
activation |
15 |
| 0 |
1 |
resistance |
2 |
|
above |
1 |
inactive |
1 |
|
new |
15 |
| both |
1 |
must |
2 |
|
could |
1 |
underwent |
1 |
|
importance |
15 |
| from |
1 |
symptoms |
2 |
|
resistant |
1 |
likely |
1 |
|
recent |
15 |
| ion |
1 |
transmission |
2 |
|
similar |
1 |
inaccessible |
1 |
|
population |
15 |
| arrest |
1 |
lowering |
1 |
|
indefinitely |
1 |
countries |
1 |
|
study |
15 |
| therapies |
1 |
ipds |
1 |
|
inconsistent |
1 |
were |
1 |
|
particularly |
15 |
| capsid |
1 |
recurrence |
1 |
|
dogs |
1 |
outstanding |
1 |
|
potential |
15 |
| hypertension |
1 |
impacts |
1 |
|
undetectable |
1 |
unsolved |
1 |
|
under |
15 |
| 150 |
1 |
toolkit |
1 |
|
experimentally |
1 |
maintaining |
1 |
|
likely |
15 |
| spine |
1 |
positivity |
1 |
|
suspended |
1 |
therefore |
1 |
|
among |
14 |
| fat |
1 |
mrgprd |
1 |
|
biochemically |
1 |
stem |
1 |
|
effect |
14 |
| diminish |
1 |
picture |
1 |
|
robust |
1 |
intervention |
1 |
|
based |
14 |
| iron |
1 |
61 |
1 |
|
aviremic |
1 |
layer |
1 |
|
leading |
14 |
| isc |
1 |
specification |
1 |
|
are |
1 |
regarding |
1 |
|
several |
14 |
| resolution |
1 |
greater |
1 |
|
2 |
1 |
option |
1 |
|
pathway |
14 |
| those |
1 |
deposits |
1 |
|
curiously |
1 |
pistachio |
1 |
|
responsible |
14 |
| capillary |
1 |
cns |
1 |
|
speculative |
1 |
cohort |
1 |
|
active |
14 |
| were |
1 |
them |
1 |
|
molecularly |
1 |
consensus |
1 |
|
state |
14 |
| results |
1 |
factor |
1 |
|
restricted |
1 |
reflecting |
1 |
|
related |
14 |
| target |
1 |
systems |
1 |
|
allogeneic |
1 |
diagnostic |
1 |
|
functions |
14 |
| 2012 |
1 |
involved |
1 |
|
after |
1 |
that |
1 |
|
mediated |
14 |
| chromophore |
1 |
animals |
1 |
|
dielectric |
1 |
88 |
1 |
|
due |
14 |
| alters |
1 |
synapses |
1 |
|
particularly |
1 |
being |
1 |
|
life |
14 |
| 4d |
1 |
architecture |
1 |
|
patient |
1 |
on |
1 |
|
unexplored |
14 |
| erythroid |
1 |
largely |
1 |
|
circumstantial |
1 |
better |
1 |
|
surface |
14 |
| co2 |
1 |
individuals |
1 |
|
390 |
1 |
not |
1 |
|
precise |
13 |
| groups |
1 |
75 |
1 |
|
disputed |
1 |
bottleneck |
1 |
|
effective |
13 |
| promise |
1 |
hmscs |
1 |
|
generally |
1 |
entirely |
1 |
|
tumor |
13 |
| breakthroughs |
1 |
pore |
1 |
|
inactive |
1 |
completely |
1 |
|
including |
13 |
| endothelial |
1 |
yet |
1 |
|
12 |
1 |
unaffected |
1 |
|
patient |
13 |
| mtorc1 |
1 |
cso |
1 |
|
despite |
1 |
decreased |
1 |
|
cases |
13 |
| alongside |
1 |
metastasis |
1 |
|
loci |
1 |
population |
1 |
|
same |
13 |
| range |
1 |
domains |
1 |
|
trapped |
1 |
shifted |
1 |
|
still |
13 |
| cardiac |
1 |
pah |
1 |
|
silent |
1 |
why |
1 |
|
approximately |
13 |
| nanotubes |
1 |
2 |
1 |
|
dormant |
1 |
theoretical |
1 |
|
large |
13 |
| only |
1 |
compounds |
1 |
|
variance |
1 |
suspension |
1 |
|
level |
13 |
| interneuron |
1 |
ards |
1 |
|
coplanar |
1 |
reliable |
1 |
|
structural |
13 |
| disinfection |
1 |
tumorigenesis |
1 |
|
roughly |
1 |
controlled |
1 |
|
vivo |
13 |
| 78 |
1 |
deficiency |
1 |
|
arrested |
1 |
open |
1 |
|
up |
13 |
| respectively |
1 |
cements |
1 |
|
practically |
1 |
have |
1 |
|
across |
13 |
| protein |
1 |
maturation |
1 |
|
but |
1 |
bonding |
1 |
|
therapy |
13 |
| global |
1 |
resected |
1 |
|
host |
1 |
we |
1 |
|
characterized |
13 |
| proper |
1 |
iph |
1 |
|
horses |
1 |
accepted |
1 |
|
early |
13 |
| tween80 |
1 |
hepatoprotection |
1 |
|
unproven |
1 |
threat |
1 |
|
action |
13 |
| species |
1 |
traits |
1 |
|
ignorant |
1 |
5 |
1 |
|
relative |
13 |
| have |
1 |
cts |
1 |
|
ineligible |
1 |
months |
1 |
|
membrane |
13 |
| thinning |
1 |
component |
1 |
|
population |
1 |
accumulated |
1 |
|
host |
13 |
| internalized |
1 |
skepticism |
1 |
|
proteins |
1 |
phyla |
1 |
|
interactions |
13 |
| er |
1 |
plant |
1 |
|
h |
1 |
positive |
1 |
|
multiple |
13 |
| standard |
1 |
activities |
1 |
|
reliable |
1 |
compared |
1 |
|
methods |
13 |
| pharmacotherapeutic |
1 |
order |
1 |
|
widely |
1 |
third |
1 |
|
events |
13 |
| broadly |
1 |
dril |
1 |
|
50 |
1 |
uninvestigated |
1 |
|
age |
13 |
| silica |
1 |
method |
1 |
|
greater |
1 |
preferred |
1 |
|
binding |
13 |
| t153 |
1 |
micrornas |
1 |
|
7 |
1 |
off |
1 |
|
term |
12 |
| plastid |
1 |
states |
1 |
|
animal |
1 |
besides |
1 |
|
even |
12 |
| schwann |
1 |
size |
1 |
|
poised |
1 |
global |
1 |
|
critical |
12 |
| contrast |
1 |
emulsions |
1 |
|
strictly |
1 |
evaluated |
1 |
|
questions |
12 |
| paralogues |
1 |
anxiety |
1 |
|
how |
1 |
including |
1 |
|
well |
12 |
| system |
1 |
hitherto |
1 |
|
modular |
1 |
length |
1 |
|
receptor |
12 |
| infected |
1 |
virus |
1 |
|
42 |
1 |
independent |
1 |
|
unchanged |
12 |
| similar |
1 |
topologies |
1 |
|
mutualists |
1 |
mainstay |
1 |
|
common |
12 |
| neurodegenerative |
1 |
curcumin |
1 |
|
tumor |
1 |
situ |
1 |
|
single |
12 |
| interaction |
1 |
acknowledged |
1 |
|
turned |
1 |
fairly |
1 |
|
regulatory |
12 |
| foxm1 |
1 |
precipitation |
1 |
|
tethered |
1 |
accurate |
1 |
|
uncertain |
12 |
| physiology |
1 |
components |
1 |
|
primitive |
1 |
many |
1 |
|
genetic |
12 |
| 90 |
1 |
y155 |
1 |
|
11 |
1 |
often |
1 |
|
reported |
12 |
| null |
1 |
membranes |
1 |
|
pesticides |
1 |
3 |
1 |
|
growth |
12 |
| conservation |
1 |
daughter |
1 |
|
unexplained |
1 |
their |
1 |
|
key |
12 |
| cone |
1 |
practice |
1 |
|
aggressive |
1 |
just |
1 |
|
properties |
12 |
| targeting |
1 |
em |
1 |
|
sb |
1 |
40 |
1 |
|
evidence |
12 |
| causing |
1 |
faers |
1 |
|
or |
1 |
one |
1 |
|
non |
12 |
| crt |
1 |
infants |
1 |
|
within |
1 |
isolates |
1 |
|
individual |
12 |
| number |
1 |
events |
1 |
|
uncataloged |
1 |
once |
1 |
|
survival |
12 |
| injury |
1 |
levels |
1 |
|
57 |
1 |
rarity |
1 |
|
drug |
12 |
| because |
1 |
status |
1 |
|
errors |
1 |
source |
1 |
|
significantly |
12 |
| neighborhood |
1 |
bundles |
1 |
|
central |
1 |
20 |
1 |
|
inflammation |
12 |
| plants |
1 |
if1 |
1 |
|
cancer |
1 |
principle |
1 |
|
chronic |
11 |
| pge |
1 |
improvements |
1 |
|
unrecognized |
1 |
lack |
1 |
|
interval |
11 |
| nss |
1 |
factors |
1 |
|
considerable |
1 |
blinded |
1 |
|
cause |
11 |
| biologic |
1 |
products |
1 |
|
ones |
1 |
invariable |
1 |
|
suggest |
11 |
| electrode |
1 |
osa |
1 |
|
inhibited |
1 |
accounting |
1 |
|
number |
11 |
| precipitation |
1 |
ratio |
1 |
|
amorphous |
1 |
is |
1 |
|
what |
11 |
| neurodevelopmental |
1 |
conferred |
1 |
|
abstinent |
1 |
important |
1 |
|
regulated |
11 |
| confounders |
1 |
day |
1 |
|
inadequate |
1 |
poorly |
1 |
|
degrees |
11 |
| likelihood |
1 |
reflectance |
1 |
|
lifetime |
1 |
investigated |
1 |
|
months |
11 |
| communication |
1 |
capabilities |
1 |
|
fully |
1 |
pluripotent |
1 |
|
period |
11 |
| uv |
1 |
prs |
1 |
|
immobilized |
1 |
large |
1 |
|
elucidated |
11 |
| running |
1 |
irr |
1 |
|
dark |
1 |
cases |
1 |
|
progress |
11 |
| residues |
1 |
correlates |
1 |
|
gaps |
1 |
lowest |
1 |
|
immune |
11 |
| subjects |
1 |
viruses |
1 |
|
what |
1 |
disordered |
1 |
|
made |
11 |
| 1c |
1 |
ligand |
1 |
|
fragmentary |
1 |
viable |
1 |
|
causes |
11 |
| households |
1 |
nonhygroscopic |
1 |
|
that |
1 |
relative |
1 |
|
g |
11 |
| endogenous |
1 |
mr |
1 |
|
140 |
1 |
definitive |
1 |
|
differentiation |
11 |
| ebv |
1 |
mea |
1 |
|
when |
1 |
95 |
1 |
|
infections |
11 |
| as |
1 |
averages |
1 |
|
water |
1 |
what |
1 |
|
b |
11 |
| considered |
1 |
persistence |
1 |
|
nonetheless |
1 |
assembled |
1 |
|
lower |
11 |
| population |
1 |
induction |
1 |
|
16 |
1 |
competent |
1 |
|
fundamental |
11 |
| thalamocortical |
1 |
parasites |
1 |
|
vigorous |
1 |
explored |
1 |
|
roles |
11 |
| leishmania |
1 |
asd |
1 |
|
operational |
1 |
fragmented |
1 |
|
animal |
11 |
| adult |
1 |
frogs |
1 |
|
24 |
1 |
urgent |
1 |
|
method |
11 |
| mechanism |
1 |
eoe |
1 |
|
infectious |
1 |
risk |
1 |
|
nature |
11 |
| infarcted |
1 |
supplementation |
1 |
|
internalized |
1 |
limitations |
1 |
|
determined |
11 |
| instrument |
1 |
microenvironment |
1 |
|
no |
1 |
partial |
1 |
|
whereas |
11 |
| esophagitis |
1 |
epcs |
1 |
|
1177 |
1 |
dsm265 |
1 |
|
without |
10 |
| oil |
1 |
mechanotransduction |
1 |
|
insertion |
1 |
regardless |
1 |
|
mice |
10 |
| proinflammatory |
1 |
metals |
1 |
|
unrivalled |
1 |
structure |
1 |
|
types |
10 |
| catalytic |
1 |
axis |
1 |
|
susceptible |
1 |
secondary |
1 |
|
loss |
10 |
| poised |
1 |
zrs |
1 |
|
neglected |
1 |
obstacle |
1 |
|
observed |
10 |
| min |
1 |
diversity |
1 |
|
weak |
1 |
rarely |
1 |
|
global |
10 |
| conserved |
1 |
cardiomyocytes |
1 |
|
bound |
1 |
any |
1 |
|
previous |
10 |
| causal |
1 |
viraemia |
1 |
|
extremely |
1 |
coformulated |
1 |
|
prevalence |
10 |
| european |
1 |
gluten |
1 |
|
problematic |
1 |
diagnosed |
1 |
|
structures |
10 |
| llt |
1 |
climate |
1 |
|
yet |
1 |
between |
1 |
|
system |
10 |
| airflow |
1 |
obstruction |
1 |
|
candidates |
1 |
actin |
1 |
|
relationship |
10 |
| asthma |
1 |
ischemia |
1 |
|
key |
1 |
crucial |
1 |
|
local |
10 |
| dynamic |
1 |
epa |
1 |
|
wood |
1 |
samples |
1 |
|
dependent |
10 |
| far |
1 |
30mum |
1 |
|
incurable |
1 |
limited |
1 |
|
transport |
10 |
| physical |
1 |
usa300 |
1 |
|
49 |
1 |
exhibited |
1 |
|
central |
10 |
| therapeutic |
1 |
need |
1 |
|
synchronised |
1 |
|
|
|
required |
10 |
| epidemiologic |
1 |
rotavirus |
1 |
|
is |
1 |
|
|
|
show |
10 |
| biosynthetic |
1 |
steps |
1 |
|
under |
1 |
|
|
|
nearly |
10 |
| microscopic |
1 |
composition |
1 |
|
philopatric |
1 |
|
|
|
knowledge |
10 |
| different |
1 |
trials |
1 |
|
diffusible |
1 |
|
|
|
advances |
10 |
| model |
1 |
calculations |
1 |
|
underdeveloped |
1 |
|
|
|
energy |
10 |
| art |
1 |
past |
1 |
|
controversy |
1 |
|
|
|
some |
10 |
| relevant |
1 |
controversy |
1 |
|
physiological |
1 |
|
|
|
site |
10 |
| known |
1 |
neurotropism |
1 |
|
participants |
1 |
|
|
|
differences |
10 |
| associated |
1 |
diabetes |
1 |
|
mostly |
1 |
|
|
|
outcomes |
10 |
| substantial |
1 |
selection |
1 |
|
|
|
|
|
|
e |
10 |
| amorphous |
1 |
neutrons |
1 |
|
|
|
|
|
|
transfer |
10 |
| sexual |
1 |
tibia |
1 |
|
|
|
|
|
|
cost |
10 |
| process |
1 |
clots |
1 |
|
|
|
|
|
|
year |
10 |
| cpk28 |
1 |
ldkt |
1 |
|
|
|
|
|
|
reaction |
10 |
| persons |
1 |
spines |
1 |
|
|
|
|
|
|
ratio |
9 |
| distal |
1 |
vision |
1 |
|
|
|
|
|
|
diseases |
9 |
| blood |
1 |
collision |
1 |
|
|
|
|
|
|
countries |
9 |
| transplantation |
1 |
tomography |
1 |
|
|
|
|
|
|
altered |
9 |
| repair |
1 |
cardiologists |
1 |
|
|
|
|
|
|
tissues |
9 |
| asia |
1 |
manifestations |
1 |
|
|
|
|
|
|
overall |
9 |
| syndrome |
1 |
field |
1 |
|
|
|
|
|
|
cycle |
9 |
| gli1 |
1 |
arrangement |
1 |
|
|
|
|
|
|
distinct |
9 |
| academic |
1 |
airways |
1 |
|
|
|
|
|
|
sites |
9 |
| ophthalmic |
1 |
link |
1 |
|
|
|
|
|
|
constant |
9 |
| cytoskeletal |
1 |
worldwide |
1 |
|
|
|
|
|
|
respectively |
9 |
| fatal |
1 |
cmml |
1 |
|
|
|
|
|
|
small |
9 |
| disability |
1 |
molecules |
1 |
|
|
|
|
|
|
like |
9 |
| environment |
1 |
rl |
1 |
|
|
|
|
|
|
neuronal |
9 |
| synthetic |
1 |
population |
1 |
|
|
|
|
|
|
imaging |
9 |
| observed |
1 |
epitopes |
1 |
|
|
|
|
|
|
three |
9 |
| based |
1 |
source |
1 |
|
|
|
|
|
|
20 |
9 |
| artery |
1 |
impact |
1 |
|
|
|
|
|
|
association |
9 |
| ocean |
1 |
surgery |
1 |
|
|
|
|
|
|
h |
9 |
| glycan |
1 |
holocene |
1 |
|
|
|
|
|
|
groups |
9 |
| infection |
1 |
physiology |
1 |
|
|
|
|
|
|
rate |
9 |
| median |
1 |
catechin |
1 |
|
|
|
|
|
|
24 |
9 |
| within |
1 |
hierarchy |
1 |
|
|
|
|
|
|
mass |
9 |
| regrowth |
1 |
processing |
1 |
|
|
|
|
|
|
present |
9 |
| prognostic |
1 |
migration |
1 |
|
|
|
|
|
|
rapid |
9 |
| learning |
1 |
branches |
1 |
|
|
|
|
|
|
reduced |
9 |
| knowledge |
1 |
ic3b |
1 |
|
|
|
|
|
|
shown |
9 |
| microglia |
1 |
lrv |
1 |
|
|
|
|
|
|
blood |
9 |
| 1alpha |
1 |
stereochemistry |
1 |
|
|
|
|
|
|
previously |
9 |
| tumorigenesis |
1 |
alone |
1 |
|
|
|
|
|
|
materials |
9 |
| years |
1 |
eplnd |
1 |
|
|
|
|
|
|
processing |
9 |
| finding |
1 |
pancreatitis |
1 |
|
|
|
|
|
|
receptors |
9 |
| expected |
1 |
regulon |
1 |
|
|
|
|
|
|
found |
9 |
| epithelial |
1 |
cultural |
1 |
|
|
|
|
|
|
genome |
9 |
| collective |
1 |
one |
1 |
|
|
|
|
|
|
primary |
9 |
| further |
1 |
role |
1 |
|
|
|
|
|
|
per |
9 |
| achieved |
1 |
bone |
1 |
|
|
|
|
|
|
sex |
9 |
| sequence |
1 |
ypcna |
1 |
|
|
|
|
|
|
consequences |
9 |
| dissection |
1 |
fat |
1 |
|
|
|
|
|
|
evolutionary |
9 |
| made |
1 |
survival |
1 |
|
|
|
|
|
|
domain |
9 |
| maladaptive |
1 |
da |
1 |
|
|
|
|
|
|
depends |
9 |
| epileptic |
1 |
neurons |
1 |
|
|
|
|
|
|
10 |
9 |
| mitotic |
1 |
childhood |
1 |
|
|
|
|
|
|
asthma |
9 |
| correlation |
1 |
all |
1 |
|
|
|
|
|
|
cd4 |
9 |
| electronic |
1 |
gating |
1 |
|
|
|
|
|
|
increasing |
9 |
| precise |
1 |
transplant |
1 |
|
|
|
|
|
|
behavior |
8 |
| fish |
1 |
efa |
1 |
|
|
|
|
|
|
temporal |
8 |
| probability |
1 |
remodelling |
1 |
|
|
|
|
|
|
complications |
8 |
| beige |
1 |
pck2 |
1 |
|
|
|
|
|
|
progression |
8 |
| motion |
1 |
primates |
1 |
|
|
|
|
|
|
breast |
8 |
| scalability |
1 |
features |
1 |
|
|
|
|
|
|
12 |
8 |
| adjusted |
1 |
atbf |
1 |
|
|
|
|
|
|
women |
8 |
| ability |
1 |
functions |
1 |
|
|
|
|
|
|
current |
8 |
| inflamed |
1 |
identification |
1 |
|
|
|
|
|
|
strong |
8 |
| 10 |
1 |
5 |
1 |
|
|
|
|
|
|
direct |
8 |
| individual |
1 |
numbers |
1 |
|
|
|
|
|
|
dose |
8 |
| explained |
1 |
chromosomes |
1 |
|
|
|
|
|
|
regulate |
8 |
| elderly |
1 |
receptor |
1 |
|
|
|
|
|
|
involved |
8 |
| pneumonia |
1 |
pp1 |
1 |
|
|
|
|
|
|
stem |
8 |
| before |
1 |
zfs |
1 |
|
|
|
|
|
|
anti |
8 |
| dependent |
1 |
protection |
1 |
|
|
|
|
|
|
extent |
8 |
| challenge |
1 |
we |
1 |
|
|
|
|
|
|
memory |
8 |
| muscle |
1 |
degeneration |
1 |
|
|
|
|
|
|
individuals |
8 |
| function |
1 |
suicide |
1 |
|
|
|
|
|
|
alterations |
8 |
| driving |
1 |
5287 |
1 |
|
|
|
|
|
|
influence |
8 |
| lipid |
1 |
facilitation |
1 |
|
|
|
|
|
|
quality |
8 |
| marv |
1 |
bethesdensis |
1 |
|
|
|
|
|
|
circuits |
8 |
| ccr7 |
1 |
mass |
1 |
|
|
|
|
|
|
populations |
8 |
| versus |
1 |
evolution |
1 |
|
|
|
|
|
|
50 |
8 |
| basic |
1 |
fcd |
1 |
|
|
|
|
|
|
tissue |
8 |
| man |
1 |
hits |
1 |
|
|
|
|
|
|
kidney |
8 |
| five |
1 |
therapy |
1 |
|
|
|
|
|
|
substantial |
8 |
| peptide |
1 |
protein |
1 |
|
|
|
|
|
|
result |
8 |
| several |
1 |
circuitry |
1 |
|
|
|
|
|
|
bone |
8 |
| catabolism |
1 |
shedding |
1 |
|
|
|
|
|
|
synthesis |
8 |
| diabetic |
1 |
aerosols |
1 |
|
|
|
|
|
|
visual |
8 |
| suggested |
1 |
seizures |
1 |
|
|
|
|
|
|
states |
8 |
| role |
1 |
pe |
1 |
|
|
|
|
|
|
origin |
8 |
| g |
1 |
production |
1 |
|
|
|
|
|
|
dysfunction |
8 |
| gonad |
1 |
odontoblasts |
1 |
|
|
|
|
|
|
30 |
8 |
| tau |
1 |
kinetics |
1 |
|
|
|
|
|
|
interaction |
8 |
| enm |
1 |
humans |
1 |
|
|
|
|
|
|
developmental |
8 |
| methodological |
1 |
scheduling |
1 |
|
|
|
|
|
|
components |
8 |
| virulence |
1 |
strategy |
1 |
|
|
|
|
|
|
lung |
8 |
| dynamics |
1 |
phenol |
1 |
|
|
|
|
|
|
33 |
8 |
| genetic |
1 |
relationship |
1 |
|
|
|
|
|
|
learning |
8 |
| inhibitory |
1 |
irf4 |
1 |
|
|
|
|
|
|
0001 |
8 |
| upar |
1 |
c |
1 |
|
|
|
|
|
|
adjustment |
8 |
| effort |
1 |
tolerance |
1 |
|
|
|
|
|
|
severe |
8 |
| ambient |
1 |
liver |
1 |
|
|
|
|
|
|
represent |
8 |
| disorders |
1 |
operates |
1 |
|
|
|
|
|
|
health |
8 |
| 1beta |
1 |
prevalence |
1 |
|
|
|
|
|
|
cardiovascular |
8 |
| denticle |
1 |
invasion |
1 |
|
|
|
|
|
|
pathogenesis |
8 |
| discharging |
1 |
knowledge |
1 |
|
|
|
|
|
|
cortical |
8 |
| distinction |
1 |
sclc |
1 |
|
|
|
|
|
|
regarding |
8 |
| heteromers |
1 |
rsrs |
1 |
|
|
|
|
|
|
evolution |
8 |
| uptake |
1 |
percepts |
1 |
|
|
|
|
|
|
ability |
8 |
| nitrate |
1 |
barcodes |
1 |
|
|
|
|
|
|
phase |
7 |
| regenerating |
1 |
cooling |
1 |
|
|
|
|
|
|
mouse |
7 |
| bypass |
1 |
pathways |
1 |
|
|
|
|
|
|
spatial |
7 |
| icad |
1 |
uncertainty |
1 |
|
|
|
|
|
|
novel |
7 |
| out |
1 |
carbon |
1 |
|
|
|
|
|
|
death |
7 |
| dcis |
1 |
adpkd |
1 |
|
|
|
|
|
|
scarce |
7 |
| participants |
1 |
motivation |
1 |
|
|
|
|
|
|
generally |
7 |
| zone |
1 |
agriculture |
1 |
|
|
|
|
|
|
fully |
7 |
| neuronal |
1 |
arousal |
1 |
|
|
|
|
|
|
target |
7 |
| integrated |
1 |
complex |
1 |
|
|
|
|
|
|
exact |
7 |
| unique |
1 |
progenitors |
1 |
|
|
|
|
|
|
impacts |
7 |
| initiating |
1 |
puzzle |
1 |
|
|
|
|
|
|
change |
7 |
| mva |
1 |
ffls |
1 |
|
|
|
|
|
|
aspects |
7 |
| t |
1 |
hemostasis |
1 |
|
|
|
|
|
|
biology |
7 |
| epidermal |
1 |
differences |
1 |
|
|
|
|
|
|
regulating |
7 |
| equilibration |
1 |
flies |
1 |
|
|
|
|
|
|
implicated |
7 |
| osteoclast |
1 |
resurgence |
1 |
|
|
|
|
|
|
nevertheless |
7 |
| organic |
1 |
alternatively |
1 |
|
|
|
|
|
|
samples |
7 |
| brc1 |
1 |
syncope |
1 |
|
|
|
|
|
|
versus |
7 |
| hematopoietic |
1 |
scales |
1 |
|
|
|
|
|
|
diverse |
7 |
| rs1042713 |
1 |
healing |
1 |
|
|
|
|
|
|
systems |
7 |
| linked |
1 |
antagonism |
1 |
|
|
|
|
|
|
first |
7 |
| altered |
1 |
giardiasis |
1 |
|
|
|
|
|
|
mr |
7 |
| melanized |
1 |
nachrs |
1 |
|
|
|
|
|
|
affect |
7 |
| designs |
1 |
mitosis |
1 |
|
|
|
|
|
|
networks |
7 |
| reach |
1 |
eradicate |
1 |
|
|
|
|
|
|
ca |
7 |
| sand |
1 |
signal |
1 |
|
|
|
|
|
|
various |
7 |
| claustrocortical |
1 |
rejection |
1 |
|
|
|
|
|
|
synapses |
7 |
| times |
1 |
approach |
1 |
|
|
|
|
|
|
analysis |
7 |
| cytoskeleton |
1 |
juveniles |
1 |
|
|
|
|
|
|
synaptic |
7 |
| ribosome |
1 |
not |
1 |
|
|
|
|
|
|
need |
7 |
| genes |
1 |
mpnsts |
1 |
|
|
|
|
|
|
studied |
7 |
| vasovagal |
1 |
cleavage |
1 |
|
|
|
|
|
|
92 |
7 |
| regional |
1 |
conflict |
1 |
|
|
|
|
|
|
17 |
7 |
| wound |
1 |
blocks |
1 |
|
|
|
|
|
|
domains |
7 |
| availability |
1 |
organisms |
1 |
|
|
|
|
|
|
decades |
7 |
| receptors |
1 |
cord |
1 |
|
|
|
|
|
|
controlling |
7 |
| sfs |
1 |
countries |
1 |
|
|
|
|
|
|
uncharacterized |
7 |
| did |
1 |
soils |
1 |
|
|
|
|
|
|
13 |
7 |
| hur |
1 |
abnormalities |
1 |
|
|
|
|
|
|
source |
7 |
| lactobacilli |
1 |
defect |
1 |
|
|
|
|
|
|
thus |
7 |
| building |
1 |
octamer |
1 |
|
|
|
|
|
|
normal |
7 |
| pulm |
1 |
mechanics |
1 |
|
|
|
|
|
|
ligands |
7 |
| multicellular |
1 |
eoc |
1 |
|
|
|
|
|
|
derived |
7 |
| spinal |
1 |
kidney |
1 |
|
|
|
|
|
|
endogenous |
7 |
| income |
1 |
c1qtnf5 |
1 |
|
|
|
|
|
|
white |
7 |
| solvent |
1 |
attrition |
1 |
|
|
|
|
|
|
plant |
7 |
| contaminated |
1 |
pasmcs |
1 |
|
|
|
|
|
|
improved |
7 |
| histone |
1 |
secretion |
1 |
|
|
|
|
|
|
regardless |
7 |
| additionally |
1 |
pylori |
1 |
|
|
|
|
|
|
challenges |
7 |
| interval |
1 |
fashion |
1 |
|
|
|
|
|
|
internal |
7 |
| precursor |
1 |
age |
1 |
|
|
|
|
|
|
proposed |
7 |
| h |
1 |
dilatation |
1 |
|
|
|
|
|
|
plasticity |
7 |
| friendly |
1 |
silks |
1 |
|
|
|
|
|
|
contribution |
7 |
| sb |
1 |
japonica |
1 |
|
|
|
|
|
|
day |
7 |
| synthesized |
1 |
panellists |
1 |
|
|
|
|
|
|
oil |
7 |
| mortality |
1 |
while |
1 |
|
|
|
|
|
|
relatively |
7 |
| mixed |
1 |
collections |
1 |
|
|
|
|
|
|
days |
7 |
| schistosomiasis |
1 |
environments |
1 |
|
|
|
|
|
|
viral |
7 |
| transport |
1 |
mucosa |
1 |
|
|
|
|
|
|
replication |
7 |
| thousands |
1 |
follicle |
1 |
|
|
|
|
|
|
late |
7 |
| progenitor |
1 |
elderly |
1 |
|
|
|
|
|
|
efficacy |
7 |
| marine |
1 |
involvement |
1 |
|
|
|
|
|
|
promote |
7 |
| bowel |
1 |
inductors |
1 |
|
|
|
|
|
|
form |
7 |
| ovarian |
1 |
candidacy |
1 |
|
|
|
|
|
|
genomic |
7 |
| genomic |
1 |
performed |
1 |
|
|
|
|
|
|
post |
7 |
| strategy |
1 |
beams |
1 |
|
|
|
|
|
|
throughout |
7 |
| lymphatic |
1 |
healthcare |
1 |
|
|
|
|
|
|
therapeutic |
7 |
| comprised |
1 |
nar |
1 |
|
|
|
|
|
|
exposure |
7 |
| period |
1 |
transformations |
1 |
|
|
|
|
|
|
presence |
7 |
| chip |
1 |
difference |
1 |
|
|
|
|
|
|
any |
7 |
| metabolic |
1 |
long |
1 |
|
|
|
|
|
|
mutations |
7 |
| transplant |
1 |
overeating |
1 |
|
|
|
|
|
|
antibodies |
7 |
| rhinitis |
1 |
intake |
1 |
|
|
|
|
|
|
extensive |
7 |
| microbial |
1 |
contingencies |
1 |
|
|
|
|
|
|
before |
7 |
| enzymatic |
1 |
commitment |
1 |
|
|
|
|
|
|
higher |
7 |
| rare |
1 |
skeletons |
1 |
|
|
|
|
|
|
environments |
7 |
| intermolecular |
1 |
gcc |
1 |
|
|
|
|
|
|
catalytic |
7 |
| auditory |
1 |
dysfunction |
1 |
|
|
|
|
|
|
transformation |
7 |
| rnas |
1 |
ad |
1 |
|
|
|
|
|
|
men |
7 |
| sodium |
1 |
vulnerability |
1 |
|
|
|
|
|
|
diversity |
7 |
| nonmalignant |
1 |
habits |
1 |
|
|
|
|
|
|
alternative |
7 |
| conformations |
1 |
eac |
1 |
|
|
|
|
|
|
insulin |
7 |
| term |
1 |
basically |
1 |
|
|
|
|
|
|
i |
7 |
| phase |
1 |
asthma |
1 |
|
|
|
|
|
|
findings |
7 |
| coral |
1 |
pressure |
1 |
|
|
|
|
|
|
plays |
7 |
| glaucoma |
1 |
ligands |
1 |
|
|
|
|
|
|
being |
7 |
| vsmc |
1 |
initiation |
1 |
|
|
|
|
|
|
plasma |
7 |
| rhinocladiella |
1 |
will |
1 |
|
|
|
|
|
|
hazard |
6 |
| positioning |
1 |
question |
1 |
|
|
|
|
|
|
connectivity |
6 |
| smc |
1 |
sensitivity |
1 |
|
|
|
|
|
|
features |
6 |
| flcn |
1 |
dissection |
1 |
|
|
|
|
|
|
basis |
6 |
| 37 |
1 |
subgroup |
1 |
|
|
|
|
|
|
diabetes |
6 |
| drives |
1 |
cycle |
1 |
|
|
|
|
|
|
childhood |
6 |
| atmosphere |
1 |
intervals |
1 |
|
|
|
|
|
|
graft |
6 |
| childhood |
1 |
pdi |
1 |
|
|
|
|
|
|
magnitude |
6 |
| eliglustat |
1 |
fusion |
1 |
|
|
|
|
|
|
carbon |
6 |
| 30 |
1 |
cadherin |
1 |
|
|
|
|
|
|
much |
6 |
| atmospheric |
1 |
synuclein |
1 |
|
|
|
|
|
|
infected |
6 |
| neuroinfectious |
1 |
deficit |
1 |
|
|
|
|
|
|
repair |
6 |
| become |
1 |
trench |
1 |
|
|
|
|
|
|
open |
6 |
| dna |
1 |
transition |
1 |
|
|
|
|
|
|
transcription |
6 |
| described |
1 |
deposition |
1 |
|
|
|
|
|
|
containing |
6 |
| precipitates |
1 |
immunotherapy |
1 |
|
|
|
|
|
|
remains |
6 |
| soils |
1 |
cres |
1 |
|
|
|
|
|
|
coronary |
6 |
| stem |
1 |
opening |
1 |
|
|
|
|
|
|
relevance |
6 |
| 50 |
1 |
challenge |
1 |
|
|
|
|
|
|
especially |
6 |
| outstanding |
1 |
chemistry |
1 |
|
|
|
|
|
|
range |
6 |
| biotin |
1 |
discovery |
1 |
|
|
|
|
|
|
controls |
6 |
| filaments |
1 |
demand |
1 |
|
|
|
|
|
|
month |
6 |
| balance |
1 |
performance |
1 |
|
|
|
|
|
|
uv |
6 |
| aortic |
1 |
adequacy |
1 |
|
|
|
|
|
|
majority |
6 |
| patient |
1 |
domestication |
1 |
|
|
|
|
|
|
using |
6 |
| carbon |
1 |
screens |
1 |
|
|
|
|
|
|
situ |
6 |
| mdsc |
1 |
segments |
1 |
|
|
|
|
|
|
auditory |
6 |
| stadial |
1 |
sleep |
1 |
|
|
|
|
|
|
independent |
6 |
| intracellular |
1 |
pathophysiology |
1 |
|
|
|
|
|
|
against |
6 |
| toxicity |
1 |
regulation |
1 |
|
|
|
|
|
|
contrast |
6 |
| ptsd |
1 |
immunity |
1 |
|
|
|
|
|
|
beta |
6 |
| splicing |
1 |
thus |
1 |
|
|
|
|
|
|
history |
6 |
| alpha |
1 |
sources |
1 |
|
|
|
|
|
|
variability |
6 |
| conformational |
1 |
group |
1 |
|
|
|
|
|
|
input |
6 |
| flower |
1 |
traffic |
1 |
|
|
|
|
|
|
effector |
6 |
| phosphorylation |
1 |
pathogenesis |
1 |
|
|
|
|
|
|
order |
6 |
| fe |
1 |
diagnosis |
1 |
|
|
|
|
|
|
hepatitis |
6 |
| elements |
1 |
uncertainties |
1 |
|
|
|
|
|
|
therapies |
6 |
| mptp |
1 |
would |
1 |
|
|
|
|
|
|
occurs |
6 |
| granulopoiesis |
1 |
mogt |
1 |
|
|
|
|
|
|
d |
6 |
| surface |
1 |
phenotype |
1 |
|
|
|
|
|
|
lack |
6 |
| proliferative |
1 |
fork |
1 |
|
|
|
|
|
|
organic |
6 |
| theoretical |
1 |
variability |
1 |
|
|
|
|
|
|
water |
6 |
| therapy |
1 |
concentration |
1 |
|
|
|
|
|
|
fat |
6 |
| structure |
1 |
device |
1 |
|
|
|
|
|
|
deficiency |
6 |
| sealing |
1 |
rt |
1 |
|
|
|
|
|
|
contributions |
6 |
| resource |
1 |
ecd |
1 |
|
|
|
|
|
|
renal |
6 |
| chicken |
1 |
groups |
1 |
|
|
|
|
|
|
baseline |
6 |
| aa |
1 |
t2d |
1 |
|
|
|
|
|
|
traits |
6 |
| vaccination |
1 |
carriers |
1 |
|
|
|
|
|
|
identification |
6 |
| although |
1 |
findings |
1 |
|
|
|
|
|
|
numbers |
6 |
| systems |
1 |
sequence |
1 |
|
|
|
|
|
|
kinase |
6 |
| particularly |
1 |
cognition |
1 |
|
|
|
|
|
|
essential |
6 |
| plastic |
1 |
continuum |
1 |
|
|
|
|
|
|
viruses |
6 |
| resistant |
1 |
nuclei |
1 |
|
|
|
|
|
|
rnas |
6 |
| malignant |
1 |
antibodies |
1 |
|
|
|
|
|
|
muscle |
6 |
| natural |
1 |
plants |
1 |
|
|
|
|
|
|
unresolved |
6 |
| payment |
1 |
product |
1 |
|
|
|
|
|
|
identity |
6 |
| understood |
1 |
nephrogenesis |
1 |
|
|
|
|
|
|
body |
6 |
| proceeds |
1 |
enamides |
1 |
|
|
|
|
|
|
pv |
6 |
| post |
1 |
solution |
1 |
|
|
|
|
|
|
lead |
6 |
| npv |
1 |
glrx3 |
1 |
|
|
|
|
|
|
partially |
6 |
| ogt |
1 |
us |
1 |
|
|
|
|
|
|
difference |
6 |
| synaptic |
1 |
principles |
1 |
|
|
|
|
|
|
advanced |
6 |
| bone |
1 |
dvt |
1 |
|
|
|
|
|
|
detection |
6 |
| basement |
1 |
neuropathology |
1 |
|
|
|
|
|
|
showed |
6 |
| detyrosination |
1 |
genes |
1 |
|
|
|
|
|
|
index |
6 |
| replication |
1 |
disorders |
1 |
|
|
|
|
|
|
infants |
6 |
| tumors |
1 |
far |
1 |
|
|
|
|
|
|
worldwide |
6 |
| ompla |
1 |
neuroadaptations |
1 |
|
|
|
|
|
|
surgery |
6 |
| aada |
1 |
o2 |
1 |
|
|
|
|
|
|
decreased |
6 |
| autonomous |
1 |
addiction |
1 |
|
|
|
|
|
|
status |
6 |
| 19 |
1 |
degus |
1 |
|
|
|
|
|
|
vitro |
6 |
| increasing |
1 |
juvenile |
1 |
|
|
|
|
|
|
play |
6 |
| pregnant |
1 |
mixtures |
1 |
|
|
|
|
|
|
plants |
6 |
| development |
1 |
with |
1 |
|
|
|
|
|
|
patterns |
6 |
| age |
1 |
feasibility |
1 |
|
|
|
|
|
|
positive |
6 |
| transfer |
1 |
tlr10 |
1 |
|
|
|
|
|
|
associations |
6 |
| symbiotic |
1 |
latvs |
1 |
|
|
|
|
|
|
potentially |
6 |
| ec |
1 |
wtas |
1 |
|
|
|
|
|
|
humans |
6 |
| property |
1 |
consequences |
1 |
|
|
|
|
|
|
protection |
6 |
| downstream |
1 |
specificity |
1 |
|
|
|
|
|
|
nitrate |
6 |
| advances |
1 |
recognition |
1 |
|
|
|
|
|
|
area |
6 |
| genome |
1 |
insomnia |
1 |
|
|
|
|
|
|
molecules |
6 |
| bond |
1 |
fibrosis |
1 |
|
|
|
|
|
|
rna |
6 |
| water |
1 |
dapt |
1 |
|
|
|
|
|
|
less |
6 |
| thalamic |
1 |
agency |
1 |
|
|
|
|
|
|
statement |
6 |
| responses |
1 |
remodeling |
1 |
|
|
|
|
|
|
af |
6 |
| iv |
1 |
operation |
1 |
|
|
|
|
|
|
vaccination |
6 |
| contribution |
1 |
adoption |
1 |
|
|
|
|
|
|
variation |
6 |
| defined |
1 |
reinnervation |
1 |
|
|
|
|
|
|
art |
6 |
| hiv |
1 |
metabolism |
1 |
|
|
|
|
|
|
particular |
6 |
| safety |
1 |
lesions |
1 |
|
|
|
|
|
|
transplantation |
6 |
| unified |
1 |
date |
1 |
|
|
|
|
|
|
group |
6 |
| event |
1 |
guide |
1 |
|
|
|
|
|
|
set |
6 |
| external |
1 |
crc |
1 |
|
|
|
|
|
|
so |
6 |
| ad |
1 |
pwid |
1 |
|
|
|
|
|
|
field |
6 |
| ne |
1 |
populations |
1 |
|
|
|
|
|
|
strategies |
6 |
| psychotic |
1 |
coordinated |
1 |
|
|
|
|
|
|
median |
6 |
| immune |
1 |
interneurons |
1 |
|
|
|
|
|
|
investigated |
6 |
| facilitate |
1 |
nedd8 |
1 |
|
|
|
|
|
|
fe |
6 |
| so |
1 |
stis |
1 |
|
|
|
|
|
|
intracellular |
6 |
| aberrant |
1 |
cpsrp |
1 |
|
|
|
|
|
|
threshold |
6 |
| integrin |
1 |
ais |
1 |
|
|
|
|
|
|
described |
6 |
| enhancer |
1 |
engagement |
1 |
|
|
|
|
|
|
treated |
6 |
| mt |
1 |
extinction |
1 |
|
|
|
|
|
|
terminal |
6 |
| among |
1 |
men |
1 |
|
|
|
|
|
|
specificity |
6 |
| drug |
1 |
screening |
1 |
|
|
|
|
|
|
stress |
6 |
| chemotherapeutic |
1 |
rsv |
1 |
|
|
|
|
|
|
confidence |
5 |
| compared |
1 |
control |
1 |
|
|
|
|
|
|
001 |
5 |
| cas9 |
1 |
assemblies |
1 |
|
|
|
|
|
|
behaviors |
5 |
| substrate |
1 |
|
|
|
|
|
|
|
|
toward |
5 |
| pulmonary |
1 |
|
|
|
|
|
|
|
|
prevention |
5 |
| breast |
1 |
|
|
|
|
|
|
|
|
programs |
5 |
| year |
1 |
|
|
|
|
|
|
|
|
developing |
5 |
| hospital |
1 |
|
|
|
|
|
|
|
|
chain |
5 |
| disperse |
1 |
|
|
|
|
|
|
|
|
mainly |
5 |
| cervical |
1 |
|
|
|
|
|
|
|
|
tools |
5 |
| regulate |
1 |
|
|
|
|
|
|
|
|
techniques |
5 |
| stomatal |
1 |
|
|
|
|
|
|
|
|
hr |
5 |
| methionine |
1 |
|
|
|
|
|
|
|
|
increase |
5 |
| index |
1 |
|
|
|
|
|
|
|
|
develop |
5 |
| rna |
1 |
|
|
|
|
|
|
|
|
robust |
5 |
| motif |
1 |
|
|
|
|
|
|
|
|
mechanistic |
5 |
| are |
1 |
|
|
|
|
|
|
|
|
dated |
5 |
| mob |
1 |
|
|
|
|
|
|
|
|
2012 |
5 |
| incidence |
1 |
|
|
|
|
|
|
|
|
15 |
5 |
| physiological |
1 |
|
|
|
|
|
|
|
|
signals |
5 |
| virus |
1 |
|
|
|
|
|
|
|
|
downstream |
5 |
| symptom |
1 |
|
|
|
|
|
|
|
|
indicated |
5 |
| dense |
1 |
|
|
|
|
|
|
|
|
artery |
5 |
| heart |
1 |
|
|
|
|
|
|
|
|
investigation |
5 |
|
|
|
|
|
|
|
|
|
|
thought |
5 |
|
|
|
|
|
|
|
|
|
|
initiate |
5 |
|
|
|
|
|
|
|
|
|
|
since |
5 |
|
|
|
|
|
|
|
|
|
|
greater |
5 |
|
|
|
|
|
|
|
|
|
|
constrained |
5 |
|
|
|
|
|
|
|
|
|
|
free |
5 |
|
|
|
|
|
|
|
|
|
|
simple |
5 |
|
|
|
|
|
|
|
|
|
|
animals |
5 |
|
|
|
|
|
|
|
|
|
|
rich |
5 |
|
|
|
|
|
|
|
|
|
|
environment |
5 |
|
|
|
|
|
|
|
|
|
|
cortex |
5 |
|
|
|
|
|
|
|
|
|
|
acid |
5 |
|
|
|
|
|
|
|
|
|
|
solution |
5 |
|
|
|
|
|
|
|
|
|
|
inhibitory |
5 |
|
|
|
|
|
|
|
|
|
|
interact |
5 |
|
|
|
|
|
|
|
|
|
|
drive |
5 |
|
|
|
|
|
|
|
|
|
|
contributes |
5 |
|
|
|
|
|
|
|
|
|
|
four |
5 |
|
|
|
|
|
|
|
|
|
|
weighted |
5 |
|
|
|
|
|
|
|
|
|
|
natural |
5 |
|
|
|
|
|
|
|
|
|
|
distribution |
5 |
|
|
|
|
|
|
|
|
|
|
modern |
5 |
|
|
|
|
|
|
|
|
|
|
architecture |
5 |
|
|
|
|
|
|
|
|
|
|
substrate |
5 |
|
|
|
|
|
|
|
|
|
|
size |
5 |
|
|
|
|
|
|
|
|
|
|
network |
5 |
|
|
|
|
|
|
|
|
|
|
conserved |
5 |
|
|
|
|
|
|
|
|
|
|
pulmonary |
5 |
|
|
|
|
|
|
|
|
|
|
75 |
5 |
|
|
|
|
|
|
|
|
|
|
ion |
5 |
|
|
|
|
|
|
|
|
|
|
access |
5 |
|
|
|
|
|
|
|
|
|
|
pathological |
5 |
|
|
|
|
|
|
|
|
|
|
metabolism |
5 |
|
|
|
|
|
|
|
|
|
|
tumour |
5 |
|
|
|
|
|
|
|
|
|
|
beneficial |
5 |
|
|
|
|
|
|
|
|
|
|
heart |
5 |
|
|
|
|
|
|
|
|
|
|
matter |
5 |
|
|
|
|
|
|
|
|
|
|
neurons |
5 |
|
|
|
|
|
|
|
|
|
|
contribute |
5 |
|
|
|
|
|
|
|
|
|
|
pain |
5 |
|
|
|
|
|
|
|
|
|
|
resolution |
5 |
|
|
|
|
|
|
|
|
|
|
lineages |
5 |
|
|
|
|
|
|
|
|
|
|
experience |
5 |
|
|
|
|
|
|
|
|
|
|
developed |
5 |
|
|
|
|
|
|
|
|
|
|
bacterial |
5 |
|
|
|
|
|
|
|
|
|
|
hcv |
5 |
|
|
|
|
|
|
|
|
|
|
indicate |
5 |
|
|
|
|
|
|
|
|
|
|
actin |
5 |
|
|
|
|
|
|
|
|
|
|
liver |
5 |
|
|
|
|
|
|
|
|
|
|
endothelial |
5 |
|
|
|
|
|
|
|
|
|
|
absence |
5 |
|
|
|
|
|
|
|
|
|
|
persistent |
5 |
|
|
|
|
|
|
|
|
|
|
nutritional |
5 |
|
|
|
|
|
|
|
|
|
|
work |
5 |
|
|
|
|
|
|
|
|
|
|
synthetic |
5 |
|
|
|
|
|
|
|
|
|
|
gap |
5 |
|
|
|
|
|
|
|
|
|
|
production |
5 |
|
|
|
|
|
|
|
|
|
|
cardiac |
5 |
|
|
|
|
|
|
|
|
|
|
sequence |
5 |
|
|
|
|
|
|
|
|
|
|
improvement |
5 |
|
|
|
|
|
|
|
|
|
|
strategy |
5 |
|
|
|
|
|
|
|
|
|
|
interneurons |
5 |
|
|
|
|
|
|
|
|
|
|
correction |
5 |
|
|
|
|
|
|
|
|
|
|
conformational |
5 |
|
|
|
|
|
|
|
|
|
|
ii |
5 |
|
|
|
|
|
|
|
|
|
|
temperature |
5 |
|
|
|
|
|
|
|
|
|
|
er |
5 |
|
|
|
|
|
|
|
|
|
|
provide |
5 |
|
|
|
|
|
|
|
|
|
|
43 |
5 |
|
|
|
|
|
|
|
|
|
|
practice |
5 |
|
|
|
|
|
|
|
|
|
|
gas |
5 |
|
|
|
|
|
|
|
|
|
|
adverse |
5 |
|
|
|
|
|
|
|
|
|
|
l1 |
5 |
|
|
|
|
|
|
|
|
|
|
resolved |
5 |
|
|
|
|
|
|
|
|
|
|
total |
5 |
|
|
|
|
|
|
|
|
|
|
characterization |
5 |
|
|
|
|
|
|
|
|
|
|
trend |
5 |
|
|
|
|
|
|
|
|
|
|
availability |
5 |
|
|
|
|
|
|
|
|
|
|
connected |
5 |
|
|
|
|
|
|
|
|
|
|
regions |
5 |
|
|
|
|
|
|
|
|
|
|
respond |
5 |
|
|
|
|
|
|
|
|
|
|
implant |
5 |
|
|
|
|
|
|
|
|
|
|
if |
5 |
|
|
|
|
|
|
|
|
|
|
products |
5 |
|
|
|
|
|
|
|
|
|
|
negative |
5 |
|
|
|
|
|
|
|
|
|
|
addition |
5 |
|
|
|
|
|
|
|
|
|
|
selective |
5 |
|
|
|
|
|
|
|
|
|
|
diagnostic |
5 |
|
|
|
|
|
|
|
|
|
|
complete |
5 |
|
|
|
|
|
|
|
|
|
|
concentrations |
5 |
|
|
|
|
|
|
|
|
|
|
resistant |
5 |
|
|
|
|
|
|
|
|
|
|
optimal |
5 |
|
|
|
|
|
|
|
|
|
|
difficult |
5 |
|
|
|
|
|
|
|
|
|
|
almost |
5 |
|
|
|
|
|
|
|
|
|
|
very |
5 |
|
|
|
|
|
|
|
|
|
|
physical |
5 |
|
|
|
|
|
|
|
|
|
|
experimental |
5 |
|
|
|
|
|
|
|
|
|
|
stimuli |
5 |
|
|
|
|
|
|
|
|
|
|
test |
5 |
|
|
|
|
|
|
|
|
|
|
directly |
5 |
|
|
|
|
|
|
|
|
|
|
amorphous |
5 |
|
|
|
|
|
|
|
|
|
|
interest |
5 |
|
|
|
|
|
|
|
|
|
|
earth |
5 |
|
|
|
|
|
|
|
|
|
|
segregation |
5 |
|
|
|
|
|
|
|
|
|
|
must |
5 |
|
|
|
|
|
|
|
|
|
|
affected |
5 |
|
|
|
|
|
|
|
|
|
|
suggested |
5 |
|
|
|
|
|
|
|
|
|
|
glycan |
5 |
|
|
|
|
|
|
|
|
|
|
gaps |
5 |
|
|
|
|
|
|
|
|
|
|
available |
5 |
|
|
|
|
|
|
|
|
|
|
nk |
5 |
|
|
|
|
|
|
|
|
|
|
lesions |
5 |
|
|
|
|
|
|
|
|
|
|
poor |
5 |
|
|
|
|
|
|
|
|
|
|
sequences |
5 |
|
|
|
|
|
|
|
|
|
|
chromatin |
5 |
|
|
|
|
|
|
|
|
|
|
100 |
5 |
|
|
|
|
|
|
|
|
|
|
date |
5 |
|
|
|
|
|
|
|
|
|
|
incidence |
5 |
|
|
|
|
|
|
|
|
|
|
support |
5 |
|
|
|
|
|
|
|
|
|
|
targeted |
5 |
|
|
|
|
|
|
|
|
|
|
problem |
5 |
|
|
|
|
|
|
|
|
|
|
schizophrenia |
5 |
|
|
|
|
|
|
|
|
|
|
innate |
5 |
|
|
|
|
|
|
|
|
|
|
nonetheless |
5 |
|
|
|
|
|
|
|
|
|
|
recipients |
5 |
|
|
|
|
|
|
|
|
|
|
barrier |
5 |
|
|
|
|
|
|
|
|
|
|
amplification |
5 |
|
|
|
|
|
|
|
|
|
|
particle |
5 |
|
|
|
|
|
|
|
|
|
|
disorders |
5 |
|
|
|
|
|
|
|
|
|
|
o |
5 |
|
|
|
|
|
|
|
|
|
|
linked |
5 |
|
|
|
|
|
|
|
|
|
|
phosphorylation |
5 |
|
|
|
|
|
|
|
|
|
|
often |
5 |
|
|
|
|
|
|
|
|
|
|
chemistry |
5 |
|
|
|
|
|
|
|
|
|
|
fate |
5 |
|
|
|
|
|
|
|
|
|
|
lncrnas |
5 |
|
|
|
|
|
|
|
|
|
|
whose |
5 |
|
|
|
|
|
|
|
|
|
|
16 |
4 |
|
|
|
|
|
|
|
|
|
|
adult |
4 |
|
|
|
|
|
|
|
|
|
|
social |
4 |
|
|
|
|
|
|
|
|
|
|
scales |
4 |
|
|
|
|
|
|
|
|
|
|
elderly |
4 |
|
|
|
|
|
|
|
|
|
|
glucose |
4 |
|
|
|
|
|
|
|
|
|
|
adults |
4 |
|
|
|
|
|
|
|
|
|
|
extracellular |
4 |
|
|
|
|
|
|
|
|
|
|
drives |
4 |
|
|
|
|
|
|
|
|
|
|
though |
4 |
|
|
|
|
|
|
|
|
|
|
caused |
4 |
|
|
|
|
|
|
|
|
|
|
reason |
4 |
|
|
|
|
|
|
|
|
|
|
discovery |
4 |
|
|
|
|
|
|
|
|
|
|
adjusted |
4 |
|
|
|
|
|
|
|
|
|
|
transcriptional |
4 |
|
|
|
|
|
|
|
|
|
|
resulting |
4 |
|
|
|
|
|
|
|
|
|
|
confirmed |
4 |
|
|
|
|
|
|
|
|
|
|
efficiency |
4 |
|
|
|
|
|
|
|
|
|
|
co2 |
4 |
|
|
|
|
|
|
|
|
|
|
healing |
4 |
|
|
|
|
|
|
|
|
|
|
self |
4 |
|
|
|
|
|
|
|
|
|
|
few |
4 |
|
|
|
|
|
|
|
|
|
|
specification |
4 |
|
|
|
|
|
|
|
|
|
|
signalling |
4 |
|
|
|
|
|
|
|
|
|
|
european |
4 |
|
|
|
|
|
|
|
|
|
|
v |
4 |
|
|
|
|
|
|
|
|
|
|
tumors |
4 |
|
|
|
|
|
|
|
|
|
|
outcome |
4 |
|
|
|
|
|
|
|
|
|
|
intervention |
4 |
|
|
|
|
|
|
|
|
|
|
further |
4 |
|
|
|
|
|
|
|
|
|
|
basal |
4 |
|
|
|
|
|
|
|
|
|
|
heterogeneity |
4 |
|
|
|
|
|
|
|
|
|
|
abundance |
4 |
|
|
|
|
|
|
|
|
|
|
scientific |
4 |
|
|
|
|
|
|
|
|
|
|
vascular |
4 |
|
|
|
|
|
|
|
|
|
|
x |
4 |
|
|
|
|
|
|
|
|
|
|
intact |
4 |
|
|
|
|
|
|
|
|
|
|
subtypes |
4 |
|
|
|
|
|
|
|
|
|
|
shape |
4 |
|
|
|
|
|
|
|
|
|
|
phenomena |
4 |
|
|
|
|
|
|
|
|
|
|
initiation |
4 |
|
|
|
|
|
|
|
|
|
|
zikv |
4 |
|
|
|
|
|
|
|
|
|
|
full |
4 |
|
|
|
|
|
|
|
|
|
|
established |
4 |
|
|
|
|
|
|
|
|
|
|
r |
4 |
|
|
|
|
|
|
|
|
|
|
microenvironment |
4 |
|
|
|
|
|
|
|
|
|
|
mature |
4 |
|
|
|
|
|
|
|
|
|
|
circuit |
4 |
|
|
|
|
|
|
|
|
|
|
assembly |
4 |
|
|
|
|
|
|
|
|
|
|
extensively |
4 |
|
|
|
|
|
|
|
|
|
|
regulator |
4 |
|
|
|
|
|
|
|
|
|
|
hbv |
4 |
|
|
|
|
|
|
|
|
|
|
formed |
4 |
|
|
|
|
|
|
|
|
|
|
initially |
4 |
|
|
|
|
|
|
|
|
|
|
later |
4 |
|
|
|
|
|
|
|
|
|
|
effort |
4 |
|
|
|
|
|
|
|
|
|
|
mammalian |
4 |
|
|
|
|
|
|
|
|
|
|
great |
4 |
|
|
|
|
|
|
|
|
|
|
stimulation |
4 |
|
|
|
|
|
|
|
|
|
|
five |
4 |
|
|
|
|
|
|
|
|
|
|
unidentified |
4 |
|
|
|
|
|
|
|
|
|
|
facilitate |
4 |
|
|
|
|
|
|
|
|
|
|
completely |
4 |
|
|
|
|
|
|
|
|
|
|
whole |
4 |
|
|
|
|
|
|
|
|
|
|
timing |
4 |
|
|
|
|
|
|
|
|
|
|
application |
4 |
|
|
|
|
|
|
|
|
|
|
40 |
4 |
|
|
|
|
|
|
|
|
|
|
culture |
4 |
|
|
|
|
|
|
|
|
|
|
adipose |
4 |
|
|
|
|
|
|
|
|
|
|
given |
4 |
|
|
|
|
|
|
|
|
|
|
governing |
4 |
|
|
|
|
|
|
|
|
|
|
wide |
4 |
|
|
|
|
|
|
|
|
|
|
mediate |
4 |
|
|
|
|
|
|
|
|
|
|
protective |
4 |
|
|
|
|
|
|
|
|
|
|
via |
4 |
|
|
|
|
|
|
|
|
|
|
interacting |
4 |
|
|
|
|
|
|
|
|
|
|
subjects |
4 |
|
|
|
|
|
|
|
|
|
|
off |
4 |
|
|
|
|
|
|
|
|
|
|
component |
4 |
|
|
|
|
|
|
|
|
|
|
delivery |
4 |
|
|
|
|
|
|
|
|
|
|
additionally |
4 |
|
|
|
|
|
|
|
|
|
|
co |
4 |
|
|
|
|
|
|
|
|
|
|
unique |
4 |
|
|
|
|
|
|
|
|
|
|
power |
4 |
|
|
|
|
|
|
|
|
|
|
enzyme |
4 |
|
|
|
|
|
|
|
|
|
|
relevant |
4 |
|
|
|
|
|
|
|
|
|
|
reaching |
4 |
|
|
|
|
|
|
|
|
|
|
provides |
4 |
|
|
|
|
|
|
|
|
|
|
chemical |
4 |
|
|
|
|
|
|
|
|
|
|
000 |
4 |
|
|
|
|
|
|
|
|
|
|
clear |
4 |
|
|
|
|
|
|
|
|
|
|
circuitry |
4 |
|
|
|
|
|
|
|
|
|
|
upon |
4 |
|
|
|
|
|
|
|
|
|
|
removal |
4 |
|
|
|
|
|
|
|
|
|
|
embryonic |
4 |
|
|
|
|
|
|
|
|
|
|
stages |
4 |
|
|
|
|
|
|
|
|
|
|
recurrent |
4 |
|
|
|
|
|
|
|
|
|
|
curcumin |
4 |
|
|
|
|
|
|
|
|
|
|
inflammatory |
4 |
|
|
|
|
|
|
|
|
|
|
standard |
4 |
|
|
|
|
|
|
|
|
|
|
considerable |
4 |
|
|
|
|
|
|
|
|
|
|
suggests |
4 |
|
|
|
|
|
|
|
|
|
|
ancient |
4 |
|
|
|
|
|
|
|
|
|
|
food |
4 |
|
|
|
|
|
|
|
|
|
|
qol |
4 |
|
|
|
|
|
|
|
|
|
|
moderate |
4 |
|
|
|
|
|
|
|
|
|
|
34 |
4 |
|
|
|
|
|
|
|
|
|
|
progenitor |
4 |
|
|
|
|
|
|
|
|
|
|
damage |
4 |
|
|
|
|
|
|
|
|
|
|
throughput |
4 |
|
|
|
|
|
|
|
|
|
|
experiments |
4 |
|
|
|
|
|
|
|
|
|
|
similar |
4 |
|
|
|
|
|
|
|
|
|
|
expected |
4 |
|
|
|
|
|
|
|
|
|
|
reference |
4 |
|
|
|
|
|
|
|
|
|
|
aor |
4 |
|
|
|
|
|
|
|
|
|
|
77 |
4 |
|
|
|
|
|
|
|
|
|
|
mutants |
4 |
|
|
|
|
|
|
|
|
|
|
force |
4 |
|
|
|
|
|
|
|
|
|
|
generated |
4 |
|
|
|
|
|
|
|
|
|
|
histone |
4 |
|
|
|
|
|
|
|
|
|
|
implantation |
4 |
|
|
|
|
|
|
|
|
|
|
cumulative |
4 |
|
|
|
|
|
|
|
|
|
|
pathogen |
4 |
|
|
|
|
|
|
|
|
|
|
ecological |
4 |
|
|
|
|
|
|
|
|
|
|
selection |
4 |
|
|
|
|
|
|
|
|
|
|
calcium |
4 |
|
|
|
|
|
|
|
|
|
|
dominant |
4 |
|
|
|
|
|
|
|
|
|
|
clade |
4 |
|
|
|
|
|
|
|
|
|
|
variants |
4 |
|
|
|
|
|
|
|
|
|
|
sodium |
4 |
|
|
|
|
|
|
|
|
|
|
insertion |
4 |
|
|
|
|
|
|
|
|
|
|
subsets |
4 |
|
|
|
|
|
|
|
|
|
|
cross |
4 |
|
|
|
|
|
|
|
|
|
|
symptoms |
4 |
|
|
|
|
|
|
|
|
|
|
transition |
4 |
|
|
|
|
|
|
|
|
|
|
density |
4 |
|
|
|
|
|
|
|
|
|
|
success |
4 |
|
|
|
|
|
|
|
|
|
|
communication |
4 |
|
|
|
|
|
|
|
|
|
|
bound |
4 |
|
|
|
|
|
|
|
|
|
|
monitoring |
4 |
|
|
|
|
|
|
|
|
|
|
public |
4 |
|
|
|
|
|
|
|
|
|
|
true |
4 |
|
|
|
|
|
|
|
|
|
|
below |
4 |
|
|
|
|
|
|
|
|
|
|
strains |
4 |
|
|
|
|
|
|
|
|
|
|
promoting |
4 |
|
|
|
|
|
|
|
|
|
|
ligand |
4 |
|
|
|
|
|
|
|
|
|
|
six |
4 |
|
|
|
|
|
|
|
|
|
|
general |
4 |
|
|
|
|
|
|
|
|
|
|
resulted |
4 |
|
|
|
|
|
|
|
|
|
|
expansion |
4 |
|
|
|
|
|
|
|
|
|
|
determinants |
4 |
|
|
|
|
|
|
|
|
|
|
phenotype |
4 |
|
|
|
|
|
|
|
|
|
|
frequency |
4 |
|
|
|
|
|
|
|
|
|
|
assessment |
4 |
|
|
|
|
|
|
|
|
|
|
children |
4 |
|
|
|
|
|
|
|
|
|
|
implications |
4 |
|
|
|
|
|
|
|
|
|
|
numerous |
4 |
|
|
|
|
|
|
|
|
|
|
splicing |
4 |
|
|
|
|
|
|
|
|
|
|
sources |
4 |
|
|
|
|
|
|
|
|
|
|
relationships |
4 |
|
|
|
|
|
|
|
|
|
|
families |
4 |
|
|
|
|
|
|
|
|
|
|
steps |
4 |
|
|
|
|
|
|
|
|
|
|
participants |
4 |
|
|
|
|
|
|
|
|
|
|
targets |
4 |
|
|
|
|
|
|
|
|
|
|
stability |
4 |
|
|
|
|
|
|
|
|
|
|
syndrome |
4 |
|
|
|
|
|
|
|
|
|
|
until |
4 |
|
|
|
|
|
|
|
|
|
|
case |
4 |
|
|
|
|
|
|
|
|
|
|
cpk28 |
4 |
|
|
|
|
|
|
|
|
|
|
location |
4 |
|
|
|
|
|
|
|
|
|
|
acute |
4 |
|
|
|
|
|
|
|
|
|
|
mechanical |
4 |
|
|
|
|
|
|
|
|
|
|
core |
4 |
|
|
|
|
|
|
|
|
|
|
therefore |
4 |
|
|
|
|
|
|
|
|
|
|
antibody |
4 |
|
|
|
|
|
|
|
|
|
|
cytokine |
4 |
|
|
|
|
|
|
|
|
|
|
follow |
4 |
|
|
|
|
|
|
|
|
|
|
obesity |
4 |
|
|
|
|
|
|
|
|
|
|
adequate |
4 |
|
|
|
|
|
|
|
|
|
|
ill |
4 |
|
|
|
|
|
|
|
|
|
|
diet |
4 |
|
|
|
|
|
|
|
|
|
|
atp |
4 |
|
|
|
|
|
|
|
|
|
|
deep |
4 |
|
|
|
|
|
|
|
|
|
|
22 |
4 |
|
|
|
|
|
|
|
|
|
|
weight |
4 |
|
|
|
|
|
|
|
|
|
|
trial |
4 |
|
|
|
|
|
|
|
|
|
|
medical |
4 |
|
|
|
|
|
|
|
|
|
|
recognition |
4 |
|
|
|
|
|
|
|
|
|
|
homeostasis |
4 |
|
|
|
|
|
|
|
|
|
|
1alpha |
4 |
|
|
|
|
|
|
|
|
|
|
translational |
4 |
|
|
|
|
|
|
|
|
|
|
cancers |
4 |
|
|
|
|
|
|
|
|
|
|
cohort |
4 |
|
|
|
|
|
|
|
|
|
|
elements |
4 |
|
|
|
|
|
|
|
|
|
|
inhibition |
4 |
|
|
|
|
|
|
|
|
|
|
approach |
4 |
|
|
|
|
|
|
|
|
|
|
approaches |
4 |
|
|
|
|
|
|
|
|
|
|
88 |
4 |
|
|
|
|
|
|
|
|
|
|
wall |
4 |
|
|
|
|
|
|
|
|
|
|
electronic |
4 |
|
|
|
|
|
|
|
|
|
|
ni |
4 |
|
|
|
|
|
|
|
|
|
|
visits |
4 |
|
|
|
|
|
|
|
|
|
|
loci |
4 |
|
|
|
|
|
|
|
|
|
|
fibrosis |
4 |
|
|
|
|
|
|
|
|
|
|
produce |
4 |
|
|
|
|
|
|
|
|
|
|
uncertainty |
4 |
|
|
|
|
|
|
|
|
|
|
transplant |
4 |
|
|
|
|
|
|
|
|
|
|
transmission |
4 |
|
|
|
|
|
|
|
|
|
|
driving |
4 |
|
|
|
|
|
|
|
|
|
|
combination |
4 |
|
|
|
|
|
|
|
|
|
|
lc |
4 |
|
|
|
|
|
|
|
|
|
|
14 |
4 |
|
|
|
|
|
|
|
|
|
|
concentration |
4 |
|
|
|
|
|
|
|
|
|
|
48 |
4 |
|
|
|
|
|
|
|
|
|
|
intestinal |
4 |
|
|
|
|
|
|
|
|
|
|
atmospheric |
4 |
|
|
|
|
|
|
|
|
|
|
determination |
4 |
|
|
|
|
|
|
|
|
|
|
length |
4 |
|
|
|
|
|
|
|
|
|
|
treat |
4 |
|
|
|
|
|
|
|
|
|
|
reactions |
4 |
|
|
|
|
|
|
|
|
|
|
question |
4 |
|
|
|
|
|
|
|
|
|
|
involves |
4 |
|
|
|
|
|
|
|
|
|
|
widely |
4 |
|
|
|
|
|
|
|
|
|
|
each |
4 |
|
|
|
|
|
|
|
|
|
|
hours |
4 |
|
|
|
|
|
|
|
|
|
|
reductase |
4 |
|
|
|
|
|
|
|
|
|
|
initial |
4 |
|
|
|
|
|
|
|
|
|
|
did |
4 |
|
|
|
|
|
|
|
|
|
|
fact |
4 |
|
|
|
|
|
|
|
|
|
|
statistically |
4 |
|
|
|
|
|
|
|
|
|
|
markers |
4 |
|
|
|
|
|
|
|
|
|
|
sb |
4 |
|
|
|
|
|
|
|
|
|
|
safety |
4 |
|
|
|
|
|
|
|
|
|
|
incomplete |
4 |
|
|
|
|
|
|
|
|
|
|
resource |
4 |
|
|
|
|
|
|
|
|
|
|
ir |
4 |
|
|
|
|
|
|
|
|
|
|
performance |
4 |
|
|
|
|
|
|
|
|
|
|
cas9 |
4 |
|
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。